264 related articles for article (PubMed ID: 30131384)
1. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
Woods DM; Ramakrishnan R; Laino AS; Berglund A; Walton K; Betts BC; Weber JS
Clin Cancer Res; 2018 Dec; 24(24):6236-6247. PubMed ID: 30131384
[TBL] [Abstract][Full Text] [Related]
2. Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma.
Huang L; Xu Y; Fang J; Liu W; Chen J; Liu Z; Xu Q
Front Immunol; 2021; 12():654749. PubMed ID: 33936081
[TBL] [Abstract][Full Text] [Related]
3. A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
J Immunother; 2019 Sep; 42(7):265-268. PubMed ID: 31145230
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib Exerts
Ocadlikova D; Lecciso M; Broto JM; Scotlandi K; Cavo M; Curti A; Palmerini E
Front Immunol; 2021; 12():577766. PubMed ID: 33717062
[TBL] [Abstract][Full Text] [Related]
5. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ
J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732
[TBL] [Abstract][Full Text] [Related]
6. Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression.
Goodman WA; Young AB; McCormick TS; Cooper KD; Levine AD
J Immunol; 2011 Mar; 186(6):3336-45. PubMed ID: 21307288
[TBL] [Abstract][Full Text] [Related]
7. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.
Kugel CH; Douglass SM; Webster MR; Kaur A; Liu Q; Yin X; Weiss SA; Darvishian F; Al-Rohil RN; Ndoye A; Behera R; Alicea GM; Ecker BL; Fane M; Allegrezza MJ; Svoronos N; Kumar V; Wang DY; Somasundaram R; Hu-Lieskovan S; Ozgun A; Herlyn M; Conejo-Garcia JR; Gabrilovich D; Stone EL; Nowicki TS; Sosman J; Rai R; Carlino MS; Long GV; Marais R; Ribas A; Eroglu Z; Davies MA; Schilling B; Schadendorf D; Xu W; Amaravadi RK; Menzies AM; McQuade JL; Johnson DB; Osman I; Weeraratna AT
Clin Cancer Res; 2018 Nov; 24(21):5347-5356. PubMed ID: 29898988
[No Abstract] [Full Text] [Related]
8. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.
Kong LY; Wei J; Sharma AK; Barr J; Abou-Ghazal MK; Fokt I; Weinberg J; Rao G; Grimm E; Priebe W; Heimberger AB
Cancer Immunol Immunother; 2009 Jul; 58(7):1023-32. PubMed ID: 19002459
[TBL] [Abstract][Full Text] [Related]
9. Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade.
Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
Br J Dermatol; 2020 May; 182(5):1214-1220. PubMed ID: 31361026
[TBL] [Abstract][Full Text] [Related]
10. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
Mozzillo N; Ascierto P
Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
[TBL] [Abstract][Full Text] [Related]
11. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
12. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells.
Park HJ; Park JS; Jeong YH; Son J; Ban YH; Lee BH; Chen L; Chang J; Chung DH; Choi I; Ha SJ
J Immunol; 2015 Jun; 194(12):5801-11. PubMed ID: 25934860
[TBL] [Abstract][Full Text] [Related]
13. Human CD39
Magid-Bernstein JR; Rohowsky-Kochan CM
J Interferon Cytokine Res; 2017 Apr; 37(4):153-164. PubMed ID: 28387597
[TBL] [Abstract][Full Text] [Related]
14. OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.
Lai C; August S; Albibas A; Behar R; Cho SY; Polak ME; Theaker J; MacLeod AS; French RR; Glennie MJ; Al-Shamkhani A; Healy E
Clin Cancer Res; 2016 Aug; 22(16):4236-48. PubMed ID: 27034329
[TBL] [Abstract][Full Text] [Related]
15. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.
Wang W; Lau R; Yu D; Zhu W; Korman A; Weber J
Int Immunol; 2009 Sep; 21(9):1065-77. PubMed ID: 19651643
[TBL] [Abstract][Full Text] [Related]
16. In-vitro effect of pembrolizumab on different T regulatory cell subsets.
Toor SM; Syed Khaja AS; Alkurd I; Elkord E
Clin Exp Immunol; 2018 Feb; 191(2):189-197. PubMed ID: 28963773
[TBL] [Abstract][Full Text] [Related]
17. Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction.
Niu J; Jiang C; Li C; Liu L; Li K; Jian Z; Gao T
Cancer Immunol Immunother; 2011 Aug; 60(8):1109-18. PubMed ID: 21547596
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy influences the accelerated age-dependent T-helper cell differentiation in systemic lupus erythematosus remission patients.
Schaier M; Gottschalk C; Uhlmann L; Speer C; Kälble F; Eckstein V; Müller-Tidow C; Meuer S; Mahnke K; Lorenz HM; Zeier M; Steinborn A
Arthritis Res Ther; 2018 Dec; 20(1):278. PubMed ID: 30563559
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.
Toker A; Nguyen LT; Stone SC; Yang SYC; Katz SR; Shaw PA; Clarke BA; Ghazarian D; Al-Habeeb A; Easson A; Leong WL; McCready DR; Reedijk M; Guidos CJ; Pugh TJ; Bernardini MQ; Ohashi PS
Clin Cancer Res; 2018 Nov; 24(22):5685-5696. PubMed ID: 30065096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
